Betting nitric oxide therapeutics can succeed in skin
This article was originally published in Start Up
Nitric oxide (NO) became a sudden celebrity in the early 1990s, as scientists recognized that the gas long known as a component of cigarette smoke and smog is also a vital chemical messenger within the body, but no one has yet been able to channel the academic understanding of NO into successful new medicines. Novan Inc. believes it can succeed where others have failed – the start-up aims first to create a topical treatment for acne, and then to pursue other first-in-class treatments in the field of dermatology.
You may also be interested in...
Nitric oxide-releasing SB206 missed the primary endpoint in a pair of Phase III studies, but Novan hopes a third study and success on a secondary endpoint still can lead to filing for approval.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.